Zymeworks

Update in progress

ZYME (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Zymeworks is a biotechnology company developing biotherapeutics for cancer, inflammation, and autoimmune diseases. Its platforms include Azymetric multispecific antibodies, a Drug Conjugate platform with proprietary cytotoxins, EFECT Fc modifications, and ProTECT tumor-specific immune co-stimulation. Lead candidates include Ziihera (zanidatamab-hrii), zanidatamab, Pasritamig, and ZW-series ADCs and bispecifics. Based in Middletown, Delaware, since 2003.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.08; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited States
CEOMr. Kenneth H. Galbraith C.A.
Founded2003
Employees231
Websitewww.zymeworks.com

Identifiers

ISINUS98985Y1082
FIGIBBG019XSYC89
CUSIP98985W102
CIK0001403752